In vitro study to make sure the drug doesn’t change generic make up of a cell is one of the 2 key studies to complete IND approval for phase 2 with the FDA next year. Company doing its thing and ticking off major milestones before the first human dose in a couple of weeks time and before Walter Reed results. The company as stated many times is funded for the period ahead and have major non dilutive funding they are working on with the US defence force after Walter Reed results which based off mechanism of action look very strong
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.035(17.5%) |
Mkt cap ! $49.56M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 23.5¢ | 20.0¢ | $405.2K | 1.907M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31257 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 103993 | 4 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |